Levosimendan
Levosimendan is a calcium sensitizer that stabilizes troponin C, activates ATP-sensitive K+ channels, and inhibits phosphodiesterases (PDEs). Levosimendan is clinically used to treat heart failure, as it improves cardiac performance and myocardial contractility without increasing oxygen consumption or decreasing preload or afterload. Levosimendan exhibits vasodilatory and cardioprotective activities, improving left ventricular function in animal models of myocardial ischemia/reperfusion.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18940212
| Cas No. |
141505-33-1 |
|---|---|
| Purity |
≥98% |
| Formula |
C14H12N6O |
| Formula Wt. |
280.28 |
| Chemical Name |
Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone |
| IUPAC Name |
2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile |
| Synonym |
Simdax |
| Melting Point |
210-214°C |
| Solubility |
Insoluble in water (0.04 mg/ml), soluble in DMSO (>50 mg/ml). |
| Appearance |
Yellow Crystalline Powder |
Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther. 2013 Oct;38(5):341-9. PMID: 23594161.
Malmberg M, Vähäsilta T, Saraste A, et al. Intracoronary Levosimendan during Ischemia Prevents Myocardial Apoptosis. Front Physiol. 2012 Feb 14;3:17. PMID: 22347864.
Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7. PMID: 21784540.
Milligan DJ, Fields AM. Levosimendan: calcium sensitizer and inodilator. Anesthesiol Clin. 2010 Dec;28(4):753-60. PMID: 21074750.
